Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(6 sites)
United States
USC/Norris Comprehensive Cancer Center, Los Angeles, California START Midwest, Grand Rapids, Michigan John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania Australia
Tasman Oncology Research, Southport, Queensland Canada
Princess Margaret Cancer Centre, Toronto, Ontario